Top Markets
#1 Akedo Akedo +54.06%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.26%
#4 Cross Cross +47.18%
#5 Black Phoenix Black Phoenix +34.15%
#6 Velvet Velvet +31.77%
#7 OVERTAKE OVERTAKE +18.70%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.05%
#9 Movement Movement +13.43%
#10 Perle Perle +11.98%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
RepliCel Life Sciences Inc. RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc.

RP
Rank in Stocks #38777
Headquartered in Vancouver, Canada, RepliCel Life Sciences Inc. is a... Headquartered in Vancouver, Canada, RepliCel Life Sciences Inc. is a regenerative medicine company dedicated to developing innovative autologous cell therapies. These treatments are designed to correct functional cellular deficiencies by harnessing a patient's own cells. The process involves isolating cells from harvested tissues, significantly expanding them in a controlled laboratory environment, and subsequently applying them therapeutically. The company's developmental portfolio includes several key product candidates: RCT-01 targets chronic tendinosis, RCS-01 addresses aging and sun-damaged skin, and RCH-01 is aimed at treating hair loss. Additionally, RepliCel is advancing RCI-02, a specialized dermal injection device. RepliCel has established significant strategic alliances. It holds a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. to establish a clinical research program and facilitate the commercialization of RCS-01 and RCT-01. A similar collaboration exists with Shiseido Company, Limited, focusing on the clinical research program for RCH-01. Furthermore, the company is engaged in a research project agreement with the University of British Columbia, contributing to the creation of a comprehensive hair follicle cell data map.
Share Price
$0.01100905
Last synced: 2025-02-28
Market Cap
$810.02K
Change (1 day)
58.98%
Change (1 year)
0.00%
Country
CA
Trade RepliCel Life Sciences Inc. (RP)

Category

Healthcare
Revenue for RepliCel Life Sciences Inc. (RP)
Revenue in Aug 2026 TTM: 0
According to RepliCel Life Sciences Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for RepliCel Life Sciences Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE